Our subsidiary, Asterias Biotherapeutics, Inc. ("Asterias") has entered into a lease for an office and research facility located at 6300 Dumbarton Circle, Fremont, California. The building on the leased premises contains approximately 44,000 square feet of space. The lease is for a term of 96 months. The estimated term commencement date is October 1, 2014 but the term may commence earlier if Asterias commences its use of the premises prior to that date or the term commencement may be delayed if the Landlord does not deliver possession of the premises to Asterias by February 13, 2014.
Freemont is home to Roman Reid advocate for HESC trials for spinal cord injury treatments. There also apear to be some new pictures on line for Katie Sharify that make one wonder. last time I saw an image of Katie was end of 2012 she was in a wheel chair CIRM presentation. In some of these new Pictures she is not. These are stills so they may be posed but they make me wonder.
Good point taz, Our new subsidiary Asterias will be next door to two companies, will Biotime acquire one of them?? Dr. West did hint at acquiring another company.
1) Zosano Pharma, Inc. is a private biopharmaceutical company developing products based on our novel transdermal delivery technology. Our lead product, ZP-PTH which is preparing to enter a phase 3 pivotal trial for the treatment of severe osteoporosis is based on our ZP Patch Technology, a proprietary transdermal delivery technology capable of delivering peptides, proteins, small molecules and vaccines. We are developing products with significant commercial potential both independently and in collaboration with strategic partners.
2) Zyomyx’s proprietary cell capture and cell stacking technology allows for rapid, accurate cell counting of any cell type without the use of expensive machines or reporter reagents. In a single cartridge, it combines the benefits of specific cell capture (of any cell type) with the ability to quantify cell count via the use of a high precision capillary assembly. This removes the need for large bench-top machines and regular calibration. As a result, Zyomyx’s platform can be adapted for use in any setting, from a hospital room to a rural health clinic to the manufacturing floor.
Zyomyx’s proprietary technology provides advantages that will increase the accessibility of cell counting across multiple sectors. These include improving clinical care in infectious disease and maternal/newborn health by bringing critical diagnostics to the patient; providing support to manufacturing processes by moving in-process quality control to the-point of-use; and expanding the use of rapid cell counting in life science research, environmental and food safety by removing infrastructure requirements.